Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Kalaris Therapeutics, Inc./ 3

Initial Beneficial Ownership · 3

Kalaris Therapeutics, Inc.

KLRSNASDAQEQUITYCurrent

Initial Beneficial Ownership

Filed Aug 3, 2026Accepted Aug 3, 2026, 4:02 PM EDTFiling CIK 1754068Accession 0001193125-26-330516
View company →Permanent SEC source ↗
Share

Structured filing — 3

ownership.xml

Open full document ↗

Filing details

Report period
2026-08-01
Issuer
Kalaris Therapeutics, Inc.
Issuer CIK
0001754068
Trading symbol
KLRS
No securities owned
Checked

Reporting owner 1

Name
KEATING LAURIE
Reporting owner CIK
0001620743
Relationship
Director
Address
C/O KALARIS THERAPEUTICS, INC., 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922

Remarks

Exhibit 24.1 - Power of Attorney

Signature 1

Signed
/s/ Andrew Oxtoby, Attorney-in-Fact
Date
2026-08-03

Filed exhibits

Company context

Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. Founded by renowned scientist Dr. Napoleone Ferrara, whose pioneering research led to the development of anti-VEGF therapy, the company is committed to advancing novel therapeutic approaches for patients with sight-threatening retinal conditions with major unmet medical needs.

Current securities

KLRSNASDAQ · EQUITY · Current

Recent company filings

  1. 4 filingAug 28, 2026
  2. 10-Q filingAug 11, 2026
  3. Results of Operations and Financial ConditionAug 11, 2026
  4. 4 filingAug 3, 2026
  5. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsJul 20, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.